ENG and in situ carcinoma: Median plasma levels of endoglin were significantly higher among patients with adverse pathologic features such as lymphovascular invasion (p < 0.001), lymph node metastasis (p < 0.001), contaminant CIS (p < 0.01), and advanced pathologic tumor stage (p < 0.001).